ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 1323

Gastrointestinal Involvement in Juvenile Systemic Sclerosis: Development of Recommendations for Screening and Investigation

Ivan Foeldvari1, Clare Pain2, Tamás Constantin3, Eileen Baildam4, Henning Lenhartz5, Michael Blakley6, Dana Nemkova7 and Clarissa A Pilkington8, 1Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, 2Pediatric Rheumatology, University Children´s Hospital, Liverpool, United Kingdom, 3Pediatric Rheumatology, University Childrens Hospital, Budapest, Hungary, 4Paediatric Rheumatology, Alder Hey Children's Foundation NHS Trust, Liverpool, United Kingdom, 5Pediatric Gastroenterology, Wilhelmstift, Hamburg, Germany, 6Internal Medicine and Pediatrics, Indiana University School of Medicine and Riley Hospital for Children at IU Health, Indianapolis, IN, 7Pedaitric Rheumatology, Prague, Czech Republic, 8Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom

Meeting: ACR/ARHP Annual Meeting 2014

Keywords: gastrointestinal complications, juvenile scleroderma and systemic sclerosis

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects: Pediatric Lupus, Scleroderma and Myositis (ACR)

Session Type: Abstract Submissions (ACR)

Background/Purpose

There are currently no agreed recommendations on how to investigate children for gastrointestinal (GI) involvement in Juvenile Systemic Sclerosis (JSSc). The aim of screening is to detect disease early to facilitate early aggressive therapy and improve outcomes. GI involvement at diagnosis incurs a worse outcome (1). Most deaths occur early in the disease course (1, 2).

 

Objectives

To develop recommendations for investigation of  GI involvement in JSSc, based on paediatric evidence and where this was lacking, consensus expert agreement.

Methods

Members of the PRES Scleroderma Working Group were invited to participate; additionally a paediatric cardiologist and paediatric gastroenterologist were invited. A nominal group technique was used. 75% consensus was defined as agreement.

Results

Table 1 shows the recommendations for screening for GI involvement at baseline and at defined time points from diagnosis. Other recommendations agreed by the group which are relevant at any stage in the disease course are as follows:

  1. Oesophageal dilatation should be assessed on any HRCT thorax performed.
  2. If any concerns regarding bleeding such as chronic anaemia, consider upper GI endoscopy.
  3. Any patient with nausea, vomiting, abdominal pain, bloating, diarrhoea or poor weight gain should undergo a hydrogen breath test for bacterial overgrowth.
  4. Consider dietetic or gastroenterology review to assess nutritional intake and status.
  5. Any patient with significant persistent GI symptoms including poor weight gain should be referred to a paediatric gastroenterologist.
  6. 6.    Table 1. Recommendations for screening for GI involvement in JSSc at baseline and follow-up (75% consensus defined as agreement).

Gastrointestinal

Baseline

All patients should have a barium swallow to assess for dysmotility or stricture and 24 hour pH monitoring for GORD and progress to upper GI endoscopy if any abnormality detected

Follow-up

Every 3 years or sooner if worsening lung involvement and/or worsening GI symptoms

Upper GI endoscopy

Barium swallow

24 hours pH monitoring

*screening guidelines are based on asymptomatic patients. However, children may need more frequent monitoring depending on clinical status and abnormalities detected on previous 

Conclusion

JSSc has a significant mortality particularly early on in the disease course. The objective of an aggressive screening program is to identify GI involvement at a stage which may be amenable to treatment. The recommendations developed by this group aim to standardise care and improve outcomes in this rare disease.

1.             Martini G, Vittadello F, Kasapcopur O, Magni Manzoni S, Corona F, Duarte-Salazar C, et al. Factors affecting survival in juvenile systemic sclerosis. Rheumatology (Oxford). 2009;48(2):119-22.

2.             Foeldvari I, Zhavania M, Birdi N, Cuttica RJ, de Oliveira SH, Dent PB, et al. Favourable outcome in 135 children with juvenile systemic sclerosis: results of a multi-national survey. Rheumatology (Oxford). 2000;39(5):556-9.


Disclosure:

I. Foeldvari,

Novartis Pharma AG, Abbott, Chugai, Genzyme,

5;

C. Pain,
None;

T. Constantin,
None;

E. Baildam,
None;

H. Lenhartz,
None;

M. Blakley,
None;

D. Nemkova,
None;

C. A Pilkington,
None.

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARHP Annual Meeting 2014

ACR Meeting Abstracts - https://acrabstracts.org/abstract/gastrointestinal-involvement-in-juvenile-systemic-sclerosis-development-of-recommendations-for-screening-and-investigation/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology